Neuphoria Therapeutics Inc.
NEUP
$4.40
$0.184.27%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 16.89% | 34.84% | -14.64% | -38.45% | -76.54% |
| Gross Profit | -17.10% | 1,216.73% | 47.21% | 38.45% | 78.75% |
| SG&A Expenses | -13.07% | 17.67% | 4.42% | -29.95% | -22.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.30% | 26.49% | -8.93% | -34.75% | -5.63% |
| Operating Income | -6.54% | 600.13% | 23.80% | 34.75% | 6.34% |
| Income Before Tax | -236.27% | 504.84% | 57.91% | 82.99% | 48.97% |
| Income Tax Expenses | -681.82% | -595.12% | 133.33% | -279.89% | 2.57% |
| Earnings from Continuing Operations | -230.62% | 505.39% | 57.33% | 85.29% | 49.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -230.62% | 505.39% | 57.33% | 85.29% | 49.28% |
| EBIT | -6.54% | 600.13% | 23.80% | 34.75% | 6.34% |
| EBITDA | -6.75% | 644.74% | 24.72% | 35.83% | 6.52% |
| EPS Basic | -39.24% | 331.35% | 76.78% | 91.89% | -101,581.82% |
| Normalized Basic EPS | 19.76% | 331.03% | 77.09% | 91.30% | -192,235.00% |
| EPS Diluted | -39.22% | 331.30% | 76.78% | 91.89% | -101,590.91% |
| Normalized Diluted EPS | 19.76% | 331.03% | 77.09% | 91.30% | -192,235.00% |
| Average Basic Shares Outstanding | 137.44% | 75.24% | 83.74% | 87.71% | -99.95% |
| Average Diluted Shares Outstanding | 137.44% | 75.24% | 83.74% | 87.71% | -99.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |